Despite a challenging 2022 for Gene Therapy developers targeting the CNS, the recent approvals of Skysona by bluebird bio and Upstaza by PTC Therapeutics have validated the potential that gene therapies can act as transformative medicines within the CNS community.

The 5th Gene Therapy for Neurological Disorders Summit is your comprehensive 4-day event to stay ahead of cutting-edge developments, overcome delivery challenges, address translational bottlenecks, and create a bulletproof clinical development strategy, to propel the next wave of CNS gene therapies forward.

This summit will unite 200+ gene therapy and neurology leaders with a program designed to cater to everyone from Discovery through to Clinical Development; this is your only opportunity for a cover-to-cover discussion full of need-to-know and practical insights.

Now that the neurological gene therapy field has been given a renewed sense of direction, this is the opportunity for the community to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders.

Read on go.evvnt.com

Continue reading at genetherapy-neurological.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share